Damien Bodet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Damien Bodet has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Adeline Bonnard
Service de Génétique du Développement, Hôpital Robert Debré, AP-HP – Université Paris-Cité, Paris, France
1 shared publication - Alain Fischer
Hôpital Necker Enfants-Malades, AP-HP Paris, Institut Imagine, Inserm U1163, Collège de France, Paris, France
1 shared publication - Alexis Bertrand
Laboratory of Genome Dynamics in the Immune System, Equipe Labellisée Ligue Contre le Cancer, INSERM UMR 1163, Imagine Institute, Université Paris Cité 7 , Paris
1 shared publication - Alice Valagussa
Laboratory of Human Lymphohematopoiesis, INSERM UMR 1163, Imagine Institute, Université Paris Cité 1 , Paris
1 shared publication - André Baruchel
Service d’Hémato-Immunologie pédiatrique, Hôpital Robert Debré, AP-HP – Université Paris-Cité, Paris, France
1 shared publication - Anna Dehler
Oncology department, University Children’s Hospital Zurich, Switzerland
1 shared publication
Latest Publications
- Open Access
LZTR1 functions as a two-hit tumor suppressor in childhood acute lymphoblastic leukemia
LZTR1 negatively regulates RAS family proteins via proteasomal degradation. Germline loss-of-function variants cause Noonan syndrome, with emerging evidence implicating LZTR1 in predisposition to childhood acute lymphoblastic leukemia (ALL), though its role in hematopoiesis remains poorly defined. Screening 1,587 children with ALL identified LZTR1 variants in 44 patients (2.8%). Germline variants were detected in 32 patients (2.0%), a frequency comparable to that observed in the general population (1.75%; 1,925/110,017; p=0.50). Somatic LZTR1 alterations were identified in 22 patients (1.4%) and were predominantly bi-allelic, arising through either a germline-plus-somatic or dual somatic configuration. They persisted at relapse. Despite enrichment in favorable-risk subtypes ( ETV6::RUNX1 , high-hyperdiploid, ERG/DUX4), bi-allelic LZTR1 -mutated cases showed delayed minimal residual disease clearance and higher late relapse risk, identifying a subgroup unsuitable for treatment de-escalation. LZTR1 expression was increased in most wild-type leukemias, consistent with a compensatory response to aberrant RAS pathway activation. Bi-allelic LZTR1 inactivation abolished RAS regulation, leading to deregulated canonical RAS expression and ectopic expression of the non-canonical RIT1 protein, whose involvement in ALL has not previously been reported. These findings establish LZTR1 as a classical tumor suppressor in ALL via a two-hit model. Monoallelic alterations show insufficient signaling perturbation and low germline penetrance, whereas bi-allelic inactivation acts as a driver event linked to a high risk of late relapse despite favorable genomics.
Open AccessLZTR1 functions as a two-hit tumor suppressor in childhood acute lymphoblastic leukemia
LZTR1 negatively regulates RAS family proteins via proteasomal degradation. Germline loss-of-function variants cause Noonan syndrome, with emerging evidence implicating LZTR1 in predisposition to childhood acute lymphoblastic leukemia (ALL), though its role in hematopoiesis remains poorly defined. Screening 1,587 children with ALL identified LZTR1 variants in 44 patients (2.8%). Germline variants were detected in 32 patients (2.0%), a frequency comparable to that observed in the general population (1.75%; 1,925/110,017; p=0.50). Somatic LZTR1 alterations were identified in 22 patients (1.4%) and were predominantly bi-allelic, arising through either a germline-plus-somatic or dual somatic configuration. They persisted at relapse. Despite enrichment in favorable-risk subtypes ( ETV6::RUNX1 , high-hyperdiploid, ERG/DUX4), bi-allelic LZTR1 -mutated cases showed delayed minimal residual disease clearance and higher late relapse risk, identifying a subgroup unsuitable for treatment de-escalation. LZTR1 expression was increased in most wild-type leukemias, consistent with a compensatory response to aberrant RAS pathway activation. Bi-allelic LZTR1 inactivation abolished RAS regulation, leading to deregulated canonical RAS expression and ectopic expression of the non-canonical RIT1 protein, whose involvement in ALL has not previously been reported. These findings establish LZTR1 as a classical tumor suppressor in ALL via a two-hit model. Monoallelic alterations show insufficient signaling perturbation and low germline penetrance, whereas bi-allelic inactivation acts as a driver event linked to a high risk of late relapse despite favorable genomics.
- Open Access
- 6 May 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (4)
Ribosomal RNA processing impairments in a B cell immunodeficient patient with WDR75 variants
Ribosomopathies are rare genetic disorders associated with abnormalities in the production and function of ribosomes. We describe here our study of a patient presenting with hypogammaglobulinemia and autism spectrum disorder. Genetic analyses revealed compound-heterozygous variants in the WDR75 gene. WDR75 encodes a component of the SSU processome, a large ribonucleoprotein complex involved in the early stages of small ribosomal subunit assembly. Functional studies in cells derived from the patient and a cell line modified by CRISPR/Cas9 showed altered processing of pre-rRNA (A0 cleavage) and increased expression of p21, suggesting a predisposition to nucleolar stress and partial activation of the p53 pathway. While these observations do not prove causality between genotype and phenotype, they suggest a possible association between WDR75 genetic variants and nuclear stress, which may contribute to the clinical presentation.
- 6 May 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (4)
Open AccessRibosomal RNA processing impairments in a B cell immunodeficient patient with WDR75 variants
Ribosomopathies are rare genetic disorders associated with abnormalities in the production and function of ribosomes. We describe here our study of a patient presenting with hypogammaglobulinemia and autism spectrum disorder. Genetic analyses revealed compound-heterozygous variants in the WDR75 gene. WDR75 encodes a component of the SSU processome, a large ribonucleoprotein complex involved in the early stages of small ribosomal subunit assembly. Functional studies in cells derived from the patient and a cell line modified by CRISPR/Cas9 showed altered processing of pre-rRNA (A0 cleavage) and increased expression of p21, suggesting a predisposition to nucleolar stress and partial activation of the p53 pathway. While these observations do not prove causality between genotype and phenotype, they suggest a possible association between WDR75 genetic variants and nuclear stress, which may contribute to the clinical presentation.